A de novo GABPA Variant in a Patient with Multifocal Cutaneous Vascular Tumors of an Unclassified Entity
Annegret HolmiD, Pascal BrouillardiD, Nagi MahammadzadeiD, Mehrnaz MehrabipouriD, Anna ShimbuluiD, Dionyssios Benetatos, Nisha LimayeiD, Ahmad Alomari, Leonard Ira ZoniD, Whitney EngiD, Harry P. KozakewichiD, Friedrich KappiD, Miikka VikkulaiD, John Butler MullikeniD, Joyce E. BischoffiD
Abstract
We investigated the genetic basis of a previously unclassified congenital vascular anomaly in a patient with multifocal cutaneous vascular tumors. Through genomic analysis, we identified a novel heterozygous de novo germline variant in GA-binding protein-alpha (GABPA), an ETS family transcription factor. Histopathologic evaluation demonstrated capillary-venous lesions lacking glucose transporter 1 expression, distinguishing this entity from common infantile hemangioma. Notably, the tumor vasculature exhibited a prominent alpha-SMA-positive perivascular cell layer, with nuclear localized GABPA detected in endothelial and perivascular cells. The GABPA c.509T>G (p.L170R) variant is absent from large population databases, including gnomAD, DeCAF, and RGC-MCPS databases, indicating it is extremely rare. The affected leucine residue is highly conserved across species and located within the Pointed (PNT) domain, a critical region mediating GABPA protein-protein interactions. AlphaMissense predicts this substitution to be highly damaging. Structure-based analysis using an AlphaFold-predicted approach, combined with in silico mutagenesis and molecular interaction analyses, revealed that the L170R substitution introduces new electrostatic interactions while disrupting native hydrophobic contacts within the PNT domain. Functional assessment in zebrafish demonstrated that mosaic stromal expression of GABPA-L170R caused abnormal vascular architecture compared with GABPA-wild-type controls, establishing a direct link between this variant and disrupted vascular development. Collectively, the genetic rarity, evolutionary conservation, predicted structural perturbation, and disruptive effects on vascular development establish GABPA-L170R as likely disease-causing variant. These findings define a new molecular mechanism underlying congenital vascular tumor formation and expand the role for ETS-family transcriptional regulation in human vascular anomalies.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genetic dysregulation of an endothelial Ras signaling network in vein of Galen malformations
Shujuan Zhao, Kedous Y. Mekbib, … Kristopher Thomas Kahle·bioRxiv·Mar 18, 2023
- De novo missense variants in SLC32A1 cause a neurodevelopmental disorder with epilepsy due to impaired GABAergic neurotransmission
Konrad Platzer, Heinrich Sticht, … Sonja M. Wojcik·Annals of NeurologyPeer-reviewed·Aug 19, 2022
- African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1
Pilar Álvarez Jerez, Peter Wild Crea, … Cornelis Blauwendraat·Nature Structural & Molecular BiologyPeer-reviewed·Dec 1, 2024
- ErbB Signalling is a Potential Therapeutic Target for Vascular Lesions with Fibrous Component
H. Ilmonen, S. Jauhiainen, … J. P. Laakkonen·bioRxiv·Sep 23, 2022
- Structural mapping of GABRB3 variants reveals genotype-phenotype correlation
Katrine M. Johannesen, Sumaiya Iqbal, … Elena Gardella·Genetics in MedicinePeer-reviewed·Dec 6, 2021
- Endothelial sampling in situ enables genetic characterization of vein of Galen Malformation
Andrew T. Hale, Shanrun Liu, … Jesse George Atherton Jones·medRxiv·Dec 1, 2023